Precigen Inc. Stock
€3.52
Your prediction
Financial data and news for Precigen
sharewise wants to provide you with the best news and tools for Precigen, so we directly link to the best financial data sources.
Financials
News
Precigen Q1 Earnings Call Highlights
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
On November 14, San Diego-based Tang Capital Management disclosed a new position in Precigen (NASDAQ:PGEN), adding approximately $40.8 million, or 12.4 million shares, per SEC filings.
According to


